Quality of life in the patients with central diabetes insipidus assessed by Nagasaki Diabetes Insipidus Questionnaire

• Material Type: 博士論文
• ISSN: 1355-008X
• Title: Quality of life in the patients with central diabetes insipidus assessed by Nagasaki Diabetes Insipidus Questionnaire
• Volume: 51 1
• Author/Editor: 野崎, 彩
• Author Heading: 野崎, 彩
• Publication, Distribution, etc.: Springer
• Publication Date: 2017-03-21
• Publication Date (W3CDTF): 2017-03-21
• Alternative Title: 新規質問票NADIQを用いた中枢性尿崩症患者のQOL評価
• Periodical title: Endocrine
• Degree grantor/type: Nagasaki University (長崎大学)
• Date Granted: 2017-03-21
• Date Granted (W3CDTF): 2017-03-21
• Dissertation Number: 甲医歯薬第919号
• Degree Type: 博士(医学)
• Conferring No. (Dissertation): 甲医歯薬第919号
• Text Language Code: eng
• Subject Heading: Diabetes insipidus; Quality of life; Questionnaire; Desmopressin
• Target Audience: 一般
• Note (General): Central diabetes insipidus (CDI) is characterized by polyuria and polydipsia due to a deficiency of vasopressin. Currently, the treatment goal for CDI is improvement of quality of life (QOL) by desmopressin (DDAVP) without developing hyponatremia. However, there is no reliable measure for QOL in CDI patients. We evaluate our original questionnaire for QOL, consisting of 12 questions focusing on polyuria, polydipsia, and DDAVP treatment, in CDI patients who underwent a switch from nasal spray to oral disintegrating tablets of DDAVP. Twenty-five CDI patients under nasal DDAVP treatment, six with newly developed CDI, and 18 healthy individuals without known polyuric/polydipsic disorders as control subjects were enrolled. QOL scores were determined by our questionnaire at the enrollment and 3 months after the start of oral DDAVP treatment and were examined by the Wilcoxon signed-rank test. Eleven questions detected improvement in QOL. The sum of the QOL scores of the eleven questions increased from 29.2 ± 5.6 under nasal to 36.8 ± 4.5 under oral DDAVP (p < 0.001). There were no clinically relevant changes in serum levels of Na. After eliminating two questions about DDAVP treatment, the sum of QOL scores was 15.3 ± 6.5 in untreated CDI patients, 24.4 ± 5.2 in those with nasal treatment, 28.9 ± 4.9 in those with oral DDAVP, and 29.5 ± 3.6 in healthy controls. The difference among groups was significant (p < 0.05 in Steel?Dwass test) except between patients treated with oral DDAVP and healthy controls. Our questionnaire can be used to accurately assess QOL in CDI patients.; 長崎大学学位論文 学位記番号:博(医歯薬)甲第919号 学位授与年月日:平成29年3月21日; Author: Aya Nozaki, Takao Ando, Satoru Akazawa, Tsuyoshi Satoh, Ikuko Sagara, Ichiro Horie, Misa Imaizumi, Toshiro Usa, Robert T. Yanagisawa, Atsushi Kawakami; Citation: Endocrine, 51(1), pp.140-147; 2016; Nagasaki University (長崎大学), 博士(医学) (2017-03-21)
• DOI: info:doi/10.1007/s12020-015-0637-3; https://doi.org/info:doi/10.1007/s12020-015-0637-3
• Persistent ID (NDL): info:ndljp/pid/10342618; https://dl.ndl.go.jp/pid/10342618
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2017-05-02T23:17:13+09:00
• Date Created (W3CDTF): 2020-12-21
• Format (IMT): PDF
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): http://hdl.handle.net/10069/37092; https://nagasaki-u.repo.nii.ac.jp/records/3901
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

Table of Contents

2021-03-07 再収集